Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313368540> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313368540 endingPage "65.28" @default.
- W4313368540 startingPage "65.28" @default.
- W4313368540 abstract "Abstract Objective Purpose of this DBPC study was to evaluate onset of action and non-inferiority of a novel low dose aqueous solution of Budesonide (“Budesolv 10μg”) to Rhinocort® aqua 64μg (RA) in adult grass pollen allergic patients. Methods Budesonide, a poorly water-soluble corticosteroid, currently marketed as suspension, was reformulated to enhance solubility and local concentration on the target mucosa. Subjects received Budesolv, the market comparator RA and placebo once daily for 8 days. Allergic symptoms were induced by 6h grass pollen challenges in the Vienna Challenge Chamber at days 1 and 8 of each treatment period. First dose was applied after 1:45h to evaluate onset of action of either treatment. Nasal, ocular, asthma symptoms and objective measures of nasal secretion and nasal obstruction were evaluated. A 95% confidence interval (CI) was calculated for difference in means between active treatments. Non-inferiority was stated if the upper limit of the CI did not exceed 115% of the reference. Onset of action was defined as first time point when the difference in nasal symptoms change from baseline between active treatment and placebo was p<0.05. Results 75 patients concluded the study per protocol. The primary endpoint (TNSS; sum of obstruction, itch, sneeze and rhinorrhoea) was met proving non-inferiority of Budesolv compared to RA. A significant difference between Budesolv and placebo was shown for TNSS 2.45 h and for total asthma score 2 h after first dose. On day 8 Budesolv 10μg was significantly better than placebo for all parameters evaluated. Conclusion Non-inferiority of Budesolv compared to Rhinocort® was shown on day 8 of treatment. Early onset of action within 3h after first dose was evident for Budesolv only." @default.
- W4313368540 created "2023-01-06" @default.
- W4313368540 creator A5003974830 @default.
- W4313368540 creator A5020077192 @default.
- W4313368540 creator A5028623286 @default.
- W4313368540 creator A5032675636 @default.
- W4313368540 creator A5060859935 @default.
- W4313368540 creator A5065701309 @default.
- W4313368540 creator A5068321758 @default.
- W4313368540 creator A5082478960 @default.
- W4313368540 creator A5087828339 @default.
- W4313368540 date "2020-05-01" @default.
- W4313368540 modified "2023-09-27" @default.
- W4313368540 title "A novel formulation of budesonide nasal spray (Budesolv 10) potentiates clinical performance in grass pollen allergic patients" @default.
- W4313368540 doi "https://doi.org/10.4049/jimmunol.204.supp.65.28" @default.
- W4313368540 hasPublicationYear "2020" @default.
- W4313368540 type Work @default.
- W4313368540 citedByCount "0" @default.
- W4313368540 crossrefType "journal-article" @default.
- W4313368540 hasAuthorship W4313368540A5003974830 @default.
- W4313368540 hasAuthorship W4313368540A5020077192 @default.
- W4313368540 hasAuthorship W4313368540A5028623286 @default.
- W4313368540 hasAuthorship W4313368540A5032675636 @default.
- W4313368540 hasAuthorship W4313368540A5060859935 @default.
- W4313368540 hasAuthorship W4313368540A5065701309 @default.
- W4313368540 hasAuthorship W4313368540A5068321758 @default.
- W4313368540 hasAuthorship W4313368540A5082478960 @default.
- W4313368540 hasAuthorship W4313368540A5087828339 @default.
- W4313368540 hasConcept C126322002 @default.
- W4313368540 hasConcept C142724271 @default.
- W4313368540 hasConcept C204787440 @default.
- W4313368540 hasConcept C27081682 @default.
- W4313368540 hasConcept C2776042228 @default.
- W4313368540 hasConcept C2776136866 @default.
- W4313368540 hasConcept C2780973058 @default.
- W4313368540 hasConcept C42219234 @default.
- W4313368540 hasConcept C44249647 @default.
- W4313368540 hasConcept C46821324 @default.
- W4313368540 hasConcept C71924100 @default.
- W4313368540 hasConcept C85663871 @default.
- W4313368540 hasConcept C90924648 @default.
- W4313368540 hasConcept C98274493 @default.
- W4313368540 hasConceptScore W4313368540C126322002 @default.
- W4313368540 hasConceptScore W4313368540C142724271 @default.
- W4313368540 hasConceptScore W4313368540C204787440 @default.
- W4313368540 hasConceptScore W4313368540C27081682 @default.
- W4313368540 hasConceptScore W4313368540C2776042228 @default.
- W4313368540 hasConceptScore W4313368540C2776136866 @default.
- W4313368540 hasConceptScore W4313368540C2780973058 @default.
- W4313368540 hasConceptScore W4313368540C42219234 @default.
- W4313368540 hasConceptScore W4313368540C44249647 @default.
- W4313368540 hasConceptScore W4313368540C46821324 @default.
- W4313368540 hasConceptScore W4313368540C71924100 @default.
- W4313368540 hasConceptScore W4313368540C85663871 @default.
- W4313368540 hasConceptScore W4313368540C90924648 @default.
- W4313368540 hasConceptScore W4313368540C98274493 @default.
- W4313368540 hasIssue "1_Supplement" @default.
- W4313368540 hasLocation W43133685401 @default.
- W4313368540 hasOpenAccess W4313368540 @default.
- W4313368540 hasPrimaryLocation W43133685401 @default.
- W4313368540 hasRelatedWork W1968412591 @default.
- W4313368540 hasRelatedWork W1969662950 @default.
- W4313368540 hasRelatedWork W1971316257 @default.
- W4313368540 hasRelatedWork W1978079965 @default.
- W4313368540 hasRelatedWork W1988456554 @default.
- W4313368540 hasRelatedWork W2001665813 @default.
- W4313368540 hasRelatedWork W2013290561 @default.
- W4313368540 hasRelatedWork W2016254027 @default.
- W4313368540 hasRelatedWork W2409805981 @default.
- W4313368540 hasRelatedWork W4313368540 @default.
- W4313368540 hasVolume "204" @default.
- W4313368540 isParatext "false" @default.
- W4313368540 isRetracted "false" @default.
- W4313368540 workType "article" @default.